A B S T R A C T Serum human growth hormone (HGH), serum immunoreactive insulin (IRI), plasma free fatty acids, and blood glucose were measured during intravenous glucose and intravenous tolbutamide tolerance tests in 13 normal and 13 prediabetic (offspring of two diabetic parents) males, closely matched for weight and age. Only prediabetics with normal glucose tolerance during oral, intravenous, and cortisone-primed glucose tolerance tests were evaluated.
INTRODUCTION
The prediabetic state has been defined as the period between conception and the time a definitive diagnosis of diabetes can be made by present methods of testing in a genetically predisposed subject (1, 2) . There is some evidence that biochemical and histological changes are already present during this period. An increase in the thickness of basement-membranes in glomerular (3) and muscle capillaries (4) , elevated fasting levels of serum insulin-like activity (ILA) (5) , and a blunted early serum insulin response with excessive later response to massive oral glucose loads have all been reported (6) .
This present study was designed to evaluate levels of serum human growth hormone, a known diabetogenic substance, and serum insulin, a key regulator of carbohydrate metabolism in normals and prediabetics. These hormones, free fatty acid concentrations, and blood sugar levels were measured during intravenous tolbutamide tolerance tests (IVTTT) and intravenous glucose tolerance tests (IVGTT) in prediabetic males (offspring of two diabetic parents) and in a control group of normal males closely matched for age and weight. Female subjects were not studied since the known sex difference in HGH concentration would have rendered evaluation of HGH levels difficult. All prediabetics showed normal blood glucose levels during oral glucose tolerance tests (100 g of glucose), during cortisone-primed oral glucose tolerance tests, and during intravenous glucose tolerance tests. Furthermore, there were no statistically significant differences between the mean blood glucose levels achieved by the normals and the prediabetics on these tests. Previous studies in normal subjects have shown that tolbutamide stimulates both HGH and IRI secretion (7, 8) , and intravenous glucose enhances insulin secretion and frequently produces rises of serum HGH 90 min or more after glucose infusion.
The data reported here indicate that: (a) prediabetic males had higher levels of serum HGH than did normal males in response to intravenous tolbutamide and glucose; (b) prediabetic males exhibited a significantly reduced serum insulin response immediately after injection of glucose; and (c) the insulin response after injection of tolbutamide in prediabetic males was not different from normal controls.
METHODS
The IVTTT and IVGTT were performed in 13 normal males, ranging in age from 19 to 43 yr (mean, 27.8 yr) and ranging from 95 to 116%o of their ideal weight1 (mean, 103.8%). None had a family history of diabetes. The 13 prediabetic males observed in this study ranged in age from 16 to 42 yr (mean, 27.8 yr), were nonobese (weight range, 96-116% of ideal weight; mean, 105.6%o), and each was an offspring of two well-documented diabetic parents. (IVTTT was performed in only 11 of the prediabetics.) All prediabetics had normal blood sugar' values during previously performed oral (100 g), intravenous (0.5 g/kg), and cortisone-primed glucose tolerance tests (9) , and except for subjects S. A. and S. R., were not related to each other. For 3 days before the IVTTT and IVGTT, the diet of all subjects contained 300 g of carbohydrate per day.
The tests were performed after an overnight fast and a 20 min period of recumbency. For the IVTTT, 1 g of tolbutamide 2 dissolved in 20 ml of saline was infused into an antecubital vein during a 3-min period. For the IVGTT, glucose (0.5 g/kg of body weight) was injected intravenously in 3 min as a 25% solution. Blood samples were drawn from an indwelling needle in an antecubital vein kept patent with a slow infusion of isotonic saline. Samples were obtained at 0, 1, 3, 5, 10, 20, 30, 40, 50, 60, 90, 120 , and 180 min after termination of the glucose or tolbutamide injection. Tables, 1959. 2 Orinase Diagnostic, 1.0 g, courtesy of the Upjohn Co., Kalamazoo, Mich.
From Metropolitan Life Insurance
Blood sugar was determined by the ferricyanide method of Hoffman, modified for use with the AutoAnalyzer (Technicon Instruments Corporation, Chauncey, N. Y.) (10) . Serum HGH and insulin (IRI) were measured by double antibody radioimmunoassay techniques (7, 11) . All HGH levels in this study were determined in a single assay in order to exclude possible fluctuations from assay to assay. The serum samples were assayed for IRI in a totally random fashion. Reproducibility in these assays was assured by using a quality control system, i.e., the same pooled serum was tested in each assay, and aliquots of the same human insulin standards were utilized in each assay.3 Free fatty acids were measured according to Dole and Meinertz (12) .
RESULTS

Blood sugar responses
The mean fasting blood sugar before the tolbutamide infusion was 76 mg/100 ml in both normals and prediabetics (Table I) . After the infusion, the mean blood sugar level decreased at 30 min to 44 mg/100 ml in normals and to 43 mg/ 100 ml in prediabetics. Thereafter, the blood sugar began to rise, but at 3 hr it was still somewhat lower than the mean fasting level.
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No)' In the prediabetics, the smallest increment seen was 0.4 (F. W.), the greatest was 79.5 mug/ml (W. J. Fig. 4 , a signifi-ever, was the difference statistically significant. cantly lower serum insulin relationship to blood
There was no significant relationship between sugar was found in the prediabetics (P < 0.01). abnormalities in growth hormone and insulin seIn order to evaluate the influence of age on the cretion in the prediabetics. Only four of the seven insulin response to intravenous glucose, normals prediabetic males with decreased or delayed peak and prediabetics were separated into three age IRI levels in response to glucose showed also exgroups. As can be seen in Table IV ,uEq/liter at 180 min in both normals and prediabetics. No significant differences were observed. IVGTT (Table I ). The stimulation of insulin secretion by glucose resulted in a greater decrease of FFA levels compared. to tolbutamide which reached nadirs of 247 pEq/liter in normals and 235 uxEq/liter in prediabetics at 60 min. Again, the mean FFA levels of normals and prediabetics were not significantly different from each other at any time throughout the tests.
DISCUSSION
The prediabetic subjects observed in this study are offspring of two diabetic parents and were not glucose intolerant during oral, intravenous, and cortisone-primed oral glucose tolerance tests. Their chance, however, of eventually becoming diabetic approaches 100%o (13) .
In this study of prediabetics and normals, closely matched for weight, age, and sex, it has been found that, although mean fasting insulin levels were not different, the insulin response to intravenous glucose was significantly diminished in prediabetics during the first 10 min of an intravenous glucose tolerance test.
After subdividing the prediabetic group into three age groups, it was apparent that the mean levels of serum IRI were lower than normal subjects at the 1, 3, 5, and 10 min intervals in all groups although only significantly so in the 15-24 yr old subgroup. The small number of subjects in each group, however, makes it difficult to evaluate the meaning of these findings, and only future studies in these selected prediabetic males might provide a clear interpretation.
An analysis of the insulin-glucose relationships during oral and cortisone-primed oral glucose tolerance tests has also been completed in the five prediabetics, age 25-34 yr, and a significantly diminished insulin-glucose relationship has been found (14) .
Besides this reduced early response, the ap- It is well known that injection of anterior pituitary extracts produce permanent diabetes mellitus in dogs and cats (19) . In man, injection of 5 mg of HGH (20) or excessive serum levels of growth hormone, such as in acromegaly, cause impairment of glucose utilization (21, 22) . Therefore, it has been long suspected that oversecretion of HGH might play a role in the pathogenesis of human diabetes mellitus.
In this study, all fasting HGH values in normals and prediabetics, with the exception of prediabetic L. A. and normal G. H., were within the normal range of 0-3 mug/ml. However, mean fasting HGH levels were found to be slightly higher in prediabetics than in normal controls on both occasions on which they were tested; and, at the beginning of the intravenous glucose tolerance test, this difference was significant. It is well known that unless fasting HGH is measured in the true basal state (at the moment of awakening), a variety of stimuli can produce significant serum HGH elevations. Therefore, it is difficult to evaluate the heterogeneity of "0 time" serum HGH levels in these normals and prediabetics because they were not truly basal, being obtained after only 20 min of recumbency. This perhaps is the reason for the differences (although not significant) in fasting mean serum HGH levels in the normals before the IVGTT and IVTTT. An earlier report by Pfeiffer (23) has reported higher levels of HGH in prediabetics compared to normals.
Our data indicate that there is a hypersecretion of HGH in prediabetics in response to tolbutamide. Furthermore, during the IVGTT 11 or 13 prediabetics showed an increase in HGH levels in response to the weak stimulus which is presumably caused by the decline of blood glucose during the intravenous glucose tolerance test (24) ; only 5 of 14 normal controls behaved similarly. It is of more than passing interest that the three prediabetics who exhibited the highest levels of serum HGH after tolbutamide (L. A., W. J., and B. D.) exhibited relatively high levels after intravenous glucose (59, 40, and 23 mttg/ml respectively at the 180 min interval; the highest, second highest, and fourth highest levels for this interval in the prediabetics). It seems reasonable to conclude from these results that the growth hormone-releasing mechanisms in prediabetics appear to be hyperresponsive to certain physiological stimuli.
It is unknown whether the overresponsiveness of the growth hormone-releasing mechanism in prediabetics is related to the malfunctioning of the /3-cell. Also, it cannot be excluded that the HGH response might be a manifestation of another diabetogenic inborn error of metabolism.
